MammaPrint Reduces Breast Cancer Overtreatment.
Results from the prospective, randomized phase III MINDACT study indicate that a subset of women with early-stage breast cancer can forego adjuvant chemotherapy. Investigators hope this eventually changes clinical practice, because unnecessary treatment places many women at risk of long-term side effects, such as cardiac toxicity, secondary cancers, and early menopause.
D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D000069342:Medical Overuse; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis